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SUMMARY
C4BP has a central role in regulating the classical complement (C0) pathway, but it is still uncertain
whether or not it is consumed during in vivo complement activation. Attempts to demonstrate changes in
C4BP plasma levels in systemic lupus erythematosus and essential mixed cryoglobulinaemia have
failed, probably due to up-regulation of this protein during the inflammatory reaction. We have studied
one patient with severe post-transfusion complement-mediated anaphylaxis (CMA), and 67 patients
with hereditary C1 inhibitor deficiency (hereditary angioedema (HAE)). The first of these two
conditions is characterized by the absence of systemic inflammatory reaction and the second by
acute and chronic activation of the C0 classical pathway. C4BP, C4BP–C4b complex, and soluble
terminal C0 complex (sC5b-9) were measured in the patients’ plasmas by ELISA techniques and C3a
and C4a by radioimmunoassays. In CMA, 15 min after the transfusion, there was a massive C0
activation, with increases in C4a, C3a, sC5b-9, C4BP–C4b complexes and decreases in C4, C3 and
C4BP. All parameters reverted to preinfusion values within 24 h. Depletion of C4 was correlated with
that of C4BP. In patients with HAE, the median value of C4BP (83% range 54–165) was significantly
lower (P < 0·0001) than in normal controls (99% range 70–159), with no difference between patients in
remission or during acute attacks. C4BP–C4b complexes could not be detected in HAE patients. The
results of this study indicate that C4BP is consumed in vivo during acute, and possibly during chronic
activation of the C0 classical pathway, and that this protein, after interaction with C4b, not longer
circulates in plasma.
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INTRODUCTION
C4BP is a large multimeric glycoprotein, being composed of six to
seven identical 70-kD chains (a-chain) and a small 45-kD chain
(b-) which are connected through disulfide bonds [1–3]. In plasma
the protein circulates in three isoforms with different subunit
compositions; the major one is a complex of 7a- and 1b-chain,
the other two are made of 6a- and no b-chain, or 6a- and 1b-chain
[4–6]. Plasma concentration is age-related, increasing from
40 mg/ml in newborns to 200-250 mg/ml in adults [7,8]. Although
there is no gender-related difference, the synthesis appears to be
influenced by sex hormones [8], being slightly increased
during pregnancy [9] or oral contraceptive treatment [10] and
reduced during androgen treatment [11]. Increased plasma levels
of C4BP have been found in vivo during inflammatory diseases
[8,12–14], and in vitro, inflammatory cytokines have been shown
to up-regulate expression of C4BP genes [15], and therefore this
protein is considered to be an acute-phase reactant.
C4BP controls the activation of the classical complement (C0)
pathway and of the coagulation system [15–17]. The a-chains bind
C4b non-covalently, acting as a cofactor to the Factor I in
C4b proteolysis and accelerating the decay of the C3 convertase
(C4b–2a complex) [18–22]. The b-chain interacts with and
inactivates the anticoagulant vitamin K-dependent protein S [16].
The interaction with protein S does not interfere with complement
inhibitory activity [23].
Although the protein is essential in controlling classical path-
way activation, very little is known about the effects of in vivo C0
activation on plasma C4BP levels. It has been shown that in
systemic lupus erythematosus (SLE), C4BP concentrations are
normal or increased, suggesting that the profound complement
activation that characterizes SLE does not increase C4BP cata-
bolism [13,24]. However, this conclusion could have been wrong
because of up-regulation of C4BP synthesis caused by the
coexisting inflammatory reaction.
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To gain insight into the involvement of C4BP in C0 activation
in vivo, we evaluated C4BP plasma levels in two conditions
characterized by acute or chronic classical pathway activation
but without any systemic inflammatory reaction.
PATIENTS AND METHODS
Patients
Complement-mediated post-transfusion anaphylaxis was studied in
a 24-year-old female with genetically determined severe von Wille-
brand factor (vWF) deficiency and high plasma levels of IgG
alloantibodies to vWF. Plasma samples were obtained before and
during severe complement-mediated anaphylaxis (CMA) triggered
by replacement therapy with vWF concentrate (for details see [25]).
Sixty-seven patients with hereditary C1 inhibitor deficiency
(hereditary angioedema (HAE)) were studied. The diagnosis of
HAE was based on personal and family history of angioedema, and
on the demonstration of low plasma levels of C1-INH activity and
of C4 [26]. Plasma samples were obtained from the 67 patients
when they were symptom-free and from seven patients also during
acute attack of angioedema. At the time of sampling no subject was
on therapy, nor there was evidence of associated diseases.
Forty healthy volunteers (20 male and 20 female) served as the
normal control group.
Blood was collected into EDTA- and Na citrate-containing
tubes, immediately centrifuged at 2500 g for 10 min, and plasma
aliquots were stored at –808C until tested. Each plasma sample was
used only once. EDTA plasma was used for complement assays
and Na citrate plasma for coagulation protein S assays.
Complement assays
C1q, C4, C3 and C1-INH antigen were measured in plasma by
single radial immunodiffusion (Nor-Partigen; Beheringwerke AG,
Marburg, Germany). Functional C1-INH was measured by
chromogenic assay (Immuno, Vienna, Austria). C4BP was
measured by ELISA as previously described [27]. sC5b-9 was
measured by ELISA (Quidel, San Diego, CA), and C4a and C3a by
competitive equilibrium radioimmunoassay (Amersham,
Aylesbury, UK).
C4BP–C4b complexes were detected in plasma samples by the
Ito method [28] with minor changes. Briefly, wells were coated
with anti-C4BP MoAb diluted in 100 mM bicarbonate buffer
pH 9·6. Rabbit anti-human C4c and peroxidase-conjugated goat
anti-rabbit IgG were used to detect C4b bound to C4BP. The
reference curve was obtained for serum, activated with heat-
aggregated IgG, serially diluted in normal EDTA plasma, diluted
1:5 in PBS containing PMSF (0·1 mM). The results were expressed
in arbitrary units (AU), assuming that a 1:2 dilution of activated
serum contained 100 AU.
Coagulation protein S assays
Total protein S (free and C4BP-bound) and free protein S con-
centrations were measured as previously described [29] and the
values expressed as percentages of the amounts in pooled normal
citrated plasma.
Other measurements
Albumin, transferrin and IgG plasma levels were measured
in plasma by single radial immunodiffusion (Nor-Partigen;
Beheringwerke AG).
Statistical analysis
Non-parametric analysis was performed by the Mann–Whitney
test. Correlation between plasma C4BP and C4 levels was assessed
by least-square linear regression.
RESULTS
Complement measurements
The patient with congenital severe vWF deficiency had normal
C1q, C1-INH, C4, C3, complement activation products (C4a, C3a,
sC5b-9) and C4BP before replacement therapy with vWF concen-
trate. Fifteen minutes after the infusion there was a massive C0
activation, shown by generation of large amounts of C4a, C3a and
sC5b-9, which was associated with profound reductions of plasma
C1q, C4, C3, C1-INH (antigen and function) and C4BP levels
(Table 1). As shown in Fig. 1, plasma C4BP levels were closely
correlated with those of C4. All complement parameters had
returned toward basal values at 24 h.
In plasma of patients with hereditary C1-INH deficiency, the
C4BP concentration was significantly lower than in controls
(P< 0·0001), without significant differences between patients in
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Table 1. Changes in plasma complement parameters before and during acute activation of the classical complement pathway
Complement parameters Basal (concentration) 15 min (% of basal) 3 h (% of basal) 24 h (% of basal)
C1q 87 (%) 57 57 68
C4 81 (%) 54 41 69
C4a 157 (ng/ml) 2227 701 106
C3 115 (%) 55 38 59
C3a 607 (ng/ml) 2742 336 95
sC5b-9 225 (ng/ml) 14222 1244 44
C1-INH function 81 (%) 77 82 108
C1-INH antigen 94 (%) 63 80 100
Haemodilution parameters
Albumin 2·690 (g/l) 85 105 98
Transferrin 0·135 (g/l) 84 106 111
IgG 0·630 (g/l) 88 80 95
Protein S (free) 72 (%) 90 92 ND
Haematocrit 27 (%) 111 126 126
remission or during acute attacks of angioedema (Table 2). As
expected, the C4 concentration was significantly lower in HAE
than in controls (P < 0·0001), with a further decrease during acute
attacks. There was no statistically significant correlation between
the levels of C4BP and those of C4.
C4BP–C4b complexes
Undiluted normal serum was incubated at 378C with heat-
aggregated IgG, samples were removed from the reaction mixture
at different times and assayed for C4BP–C4b complexes by
ELISA. In agreement with a previous report [28], we found that
in vitro the amounts of the complexes generated by C0 activation
decreased rapidly during incubation at 378C (Fig. 2). In vivo these
complexes were not detectable in controls, nor in HAE patients
(Table 2), but they could be measured in the vWF-deficient patient
in the early phase of acute C0 activation during C0-mediated
anaphylaxis (Fig. 1).
Other measurements
To evaluate the effects of haemodilution and of protein loss due to
changes in vascular permeability during CMA, we measured
haematocrit and plasma levels of non-C0-related proteins of dif-
ferent sizes. As shown in Table 1, haematocrit increased and
albumin, transferrin, protein S and IgG decreased, suggesting
plasma extravasation. However, these changes were markedly
lower than those of the C0 parameters. The concentration of total
protein S (free and bound to C4BP) correlated with that of C4BP
(Fig. 1).
DISCUSSION
The results of this study indicate that acute, and possibly chronic
activation of classical C0 pathway in vivo lead to consumption of
C4BP, as suggested by the reduction in its plasma levels. It is
unlikely that such a reduction could be due to defective recognition
of C4BP, which undergoes conformational changes following C0
activation, or to the increased vascular permeability induced by C0
anaphylatoxins. In vitro studies have demonstrated that binding to
C4b did not affect C4BP antigenicity [28], and in CMA the change
in plasma levels of the non-C0-related proteins was minimal
compared with the reductions in C4BP and C0 parameters and
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Fig. 1. In vivo acute activation of the classical complement pathway
resulted in parallel decreases of concentrations of C4, C4BP and C4BP–
S complexes and in rapid clearance from the circulation of C4BP–C4b
complexes. Arrow, Infusion of von Willebrand factor (vWF) concentrate;
%, percentage of contents of normal pooled plasma; AU, arbitrary units.
Table 2. C4, C3, C4BP and C4BP–C4b concentrations (median, range) in plasmas of patients with C1 inhibitor deficiency
(HAE) and in age-matched normal controls
Number of Age C4BP–C4b
cases (years) C4 (%) C4BP (%) C3 (%) (AU)
Controls 40 37 98 99 107 < 2
(24–66) (60–130) (70–159) (75–140)
HAE (remission) 67 33 14* 83* 95 < 2
(20–66) (1–70) (54–165) (49–137)
HAE (acute attack) 7 32 5** 76 99 < 2
(17–47) (1–9) (44–137) (80–109)
%, Percentage of contents of normal pooled plasma; AU, arbitrary unit.
*HAE versus control, P < 0·0001; **HAE (acute attack) versus HAE (remission), P< 0·0001.
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Fig. 2. Kinetics of the dissociation of C4BP–C4b complexes generated in
vitro by incubating normal human serum with heat-aggregated IgG at 378C.
Serum (100 ml) was removed from reaction mixture at different times,
mixed with equal volumes of a 1:5 dilution of normal EDTA-PMSF plasma
and assayed for C4BP–C4b complexes by ELISA. The results are
expressed as mean 6 s.d. of three experiments in duplicate.
the increases in C0 activation products (C4a, C3a, sC5b-9)
(Table 1). Previous attempts to demonstrate consumption of
C4BP during chronic activation of classical pathway have been
done in patients with SLE and essential mixed cryoglobulinaemia
(EMC) [13,24]. Both these conditions are characterized by intense
systemic inflammatory reactions, and up-regulation of C4BP
synthesis could have masked C4BP consumption. Therefore, we
are confident in concluding that the reductions of the levels of this
protein in plasma of our patients were truly the result of its
increased catabolism.
Patients with hereditary C1-INH deficiency (HAE) represent a
unique model of profound chronic activation of the classical C0
pathway in the absence of immune inflammatory events which can
influence acute reactant proteins. The large series of HAE patients
that we have presented here clearly demonstrated that C4BP levels
were significantly lower than in normal subjects (Table 2). The
absence of a significant difference between remission and attacks
suggests that the change in C4 catabolism during the attacks of
angioedema is not quantitatively relevant, probably because of the
chronically reduced levels of C4 in these patients.
In HAE the classical C0 pathway is activated efficiently but
without formation of a stable C3 convertase, as shown by the
normal levels of C3 in these patients. In vitro experiments demon-
strated that the activation of classical C0 pathway in C4BP-depleted
serum caused C3 consumption, which was instead balanced by
reconstitution with C4BP [30,31]. Therefore, it is likely that in
HAE patients, in order to block the excess formation of C3
convertase, C4BP is actively used, this then resulting in a relative
deficiency. Nevertheless, SLE patients, in whom activation of the
classical C0 pathway continues through C3, suggest that the
possibility of blocking the C3 convertase does not rely exclusively
on the presence of C4BP. The demonstration that surface-bound
C4b is more resistant to factor I-mediated inactivation than fluid-
phase C4b [32] suggests that the different conditions in which the
C3 convertase is formed (on immune complexes in SLE and in the
fluid phase due to autoactivation of C1r and C1s in HAE) probably
influence its susceptibility to inactivation by C4BP. This hypo-
thesis is consistent with the finding that in our patient with CMA, in
whom acute C0 activation was mediated by immune complexes,
C4BP was unable to control massive activation of C3 (Table 1).
As could have been predicted, based on the theoretical inter-
action between C4 and C4BP, Fig. 1 demonstrates that the con-
sumption of the two proteins was tightly correlated during acute C0
activation. However, in chronic C0 activation (HAE), we found that
even with profound C4 depletion, C4BP was only moderately
reduced (Table 2) and the levels of the two proteins were not
significantly correlated. Although no data are available on the
turnover of C4BP, the finding that in the patient with CMA C4BP
returned to basal values faster than C4 (Fig. 1) seems to indicate
that different synthesis rates for the two proteins could have been
responsible for the lack of correlation in the situation of chronic C0
activation. Alternatively, in a condition of chronic C4 deficiency,
like that of HAE patients, only limited amounts of C4b can be
released upon activation of C1, and thus less C4BP is required for
its degradation.
The observation that both acute and chronic C0 activation were
associated with decreased plasma levels of C4BP might indicate
that this protein, after interaction with C4b, no longer circulates in
plasma. That this might be the case is also supported by the finding
that C4BP–C4b complexes could be detected for only a few
minutes after triggering C0 activation and that the decrease in the
C4BP–C4b plasma level was not associated with a concomitant
increase in C4BP concentration. Furthermore, in the CMA patient
there was a rapid reduction in total protein S concentration (Fig. 1),
without any significant change in the plasma level of the free
molecule (Table 1). Since about 60% of protein S circulates in
plasma bound to C4BP, our finding supports the hypothesis that
there is increased catabolism of this protein during acute C0
activation. Whereas in the CMA patient the consumption of
C4BP could be due to its incorporation into the immune complexes
[19], in HAE it is also possible that, after the binding to C4b, C4BP
is removed from circulation through interaction with C0 receptor
(CR). However, we can not exclude that the chronically reduced
levels of C4 could lead to a down-regulation of C4BP synthesis.
In conclusion, this study provides evidence that acute, and
possibly chronic activation of the classical C0 pathway in vivo can
lead to the consumption of C4BP, and that C4BP–C4b complexes
are rapidly removed from the circulation. Despite the fact that the
levels of C4BP in HAE patients were lower than in normal
subjects, the high C4BP/C4 ratio may contribute to preventing
C3 activation in this disease.
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